HIV-1 Infections Clinical Trial
Official title:
Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network
The objective of this study is to monitor Health Outcomes of Interest (HOI) in participants with human immunodeficiency virus-1 (HIV-1) infection following treatment with Raltegravir.
Study participants contributed data to one or more of 3 cohorts: 1) Historical Cohort: HIV-infected participants treated with antiretroviral therapy in the course of ordinary clinical practice at the clinics and medical centers of Kaiser Permanente (KP) between 1 January 2000 and 12 October 2007 (date of market authorization for raltegravir in USA), 2) Concurrent Cohort: HIV-infected participant treated with a new non-raltegravir antiretroviral therapy in the course of ordinary clinical practice at the clinics and medical centers of KP on or after 12 October 2007, and 3) Raltegravir Cohort: HIV-infected participant treated with raltegravir in the course of ordinary clinical practice at the clinics and medical centers of KP on or after 12 October 2007. Participants could contribute data to more than one cohort, but no overlap in follow-up time was allowed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01013415 -
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
|
Phase 1 | |
| Active, not recruiting |
NCT02923713 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
| Completed |
NCT01151319 -
Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults
|
Phase 1 | |
| Completed |
NCT01138605 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
| Completed |
NCT01078233 -
Observational Data Analysis in EuroSIDA (MK-0518-058)
|
||
| Recruiting |
NCT02593409 -
HIV PrEP Priming of Immune Effectors
|
Phase 4 | |
| Completed |
NCT00557245 -
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
|
Phase 3 | |
| Withdrawn |
NCT00984152 -
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
|
Phase 3 | |
| Completed |
NCT00799058 -
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
|
Phase 1/Phase 2 | |
| Completed |
NCT01159275 -
Lopinavir (LPV) Dose Reduction
|
Phase 1/Phase 2 | |
| Completed |
NCT01281813 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
| Active, not recruiting |
NCT03027297 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
| Completed |
NCT01033760 -
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
|
Phase 3 | |
| Completed |
NCT01139905 -
Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children
|
Phase 2 | |
| Completed |
NCT00830804 -
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
|
Phase 2 | |
| Completed |
NCT01074931 -
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
|
N/A |